Slingshot Insights

Catalyst

Slingshot members are tracking this event:

Phase 3 initial topline data of Fovista (pegpleranib) for Wet-AMD due Q4 2016

Source Link:: http://investors.ophthotech.com/releasedetail.cfm?ReleaseID=938436

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

OPHT

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Additional Information

Additional Relevant Details announced the completion of patient recruitment for its second Phase 3 trial of Fovista (pegpleranib) in combination with Lucentis (ranibizumab) for the treatment of wet age-related macular degeneration (AMD). The Company expects to announce initial, topline data from both Phase 3 trials of Fovista in combination with Lucentis in the fourth quarter of 2016.

http://investors.oph...

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Dec 12, 2016

Occurred Source:

http://investors.ophthotech.com/releasedetail.cfm?ReleaseID=1003651

Related Projects

Fovista Phase 3 data is a major 4th Quarter Pharma Catalyst, this call will review the Phase 2 data and discuss the drug's potential for success OPHT, NVS, REGN Executed On: Nov 08, 2016 at 01:00 PM EST

Related Keywords Phase 3 Initial Topline Data, Fovista, Wet-amd, Q4 2016, Fast Track Status, Fda, Lucentis, Ranibizumab, Pegpleranib